43
Participants
Start Date
May 30, 2019
Primary Completion Date
October 17, 2022
Study Completion Date
October 31, 2022
ibalizumab-uiyk
Ibalizumab-uiyk is an Immunoglobulin G4 (IgG4) monoclonal antibody targeting domain 2 of the extracellular portion of the Cluster of Differentiation 4 (CD4) protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Orlando Immunology Center, Orlando
Gary Richmond MD, PA, Fort Lauderdale
North Texas Infectious Disease Consultants, Dallas
Anthony Mills MD Inc., Los Angeles
Collaborators (1)
Westat
OTHER
TaiMed Biologics Inc.
INDUSTRY